Form 4 for CBIO CRESCENT BIOPHARMA, INC.
Accepted 2022-03-10 00:00:00 ET · period of report 2022-03-09 · accession 0001209191-22-017968 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-03-10 | 2022-03-09 | CBIO | Girard Armand | SVP, Chief Business Off | S - Sale | $1.09 | -2,339 | 22.7K | -9% | -$2,550 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-09 | S | D | 2,339 | $1.09 | 22,661 | D | — | — | (F2) The common stock was sold by the reporting person in a series of open market transactions on the transaction date with a volume weighted average sale price of $1.09. The range of sales prices for the transactions reported was $1.09 to $1.11 per share. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |